Want to see AU:CC5 full AI Analyst Report?
LBT Innovations Limited (CC5) AI Stock Analysis
LBT Innovations Limited
(ASX:CC5)
Overall score is held down primarily by weak financial performance, highlighted by FY2026 margin collapse, a return to losses, and ongoing cash burn/negative free cash flow. Technical signals are mixed but lean weak given the stock remains below key long-term moving averages and has a negative MACD. Valuation is also constrained because losses create a negative P/E and there is no dividend yield data.
LBT Innovations Limited (CC5) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 41.46M
- Dividend Yield
- ―
- Average Volume (3M)
- 868.79K
- Price to Earnings (P/E)
- -18.9
- Beta (1Y)
- 1.63
- Revenue Growth
- -15.42%
- EPS Growth
- -210.00%
- Country
- Australia
- Employees
- 26
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Software - Infrastructure
LBT Innovations Limited Business Overview & Revenue Model
Company Description
Based in Adelaide, Australia, Clever Culture Systems Limited, established in 2004, focuses on the innovation, development, and market launch of advanced technological solutions for the medical industry. The company operates internationally, serving m...
LBT Innovations Limited Financial Statement Overview
Summary
Weak fundamentals driven by FY2026 deterioration: revenue fell ~10.7%, gross profit turned negative, and the company swung from FY2025 profit to an FY2026 net loss. Cash flow is particularly concerning with negative operating cash flow and negative free cash flow, increasing financing risk. The balance sheet shows only moderate leverage (~0.4x debt-to-equity), but past equity stress (negative equity in FY2023) and the current loss/cash burn limit financial quality.
Income Statement
28NegativeBalance Sheet
55NeutralCash Flow
22Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.48M | 4.62M | 5.46M | 1.26M | 2.13M | 2.13M |
| Gross Profit | 1.52M | -1.98M | 3.96M | 1.11M | 1.71M | 1.33M |
| EBITDA | -3.87M | -3.73M | 220.00K | -4.05M | -17.12M | -5.72M |
| Net Income | -1.86M | -2.24M | 1.68M | -3.74M | -22.52M | -6.64M |
Balance Sheet | ||||||
| Total Assets | 13.55M | 13.55M | 10.77M | 7.93M | 7.37M | 31.52M |
| Cash, Cash Equivalents and Short-Term Investments | 1.70M | 1.70M | 1.26M | 2.35M | 2.02M | 2.79M |
| Total Debt | 2.98M | 2.98M | 2.21M | 3.19M | 3.39M | 4.29M |
| Total Liabilities | 6.02M | 6.02M | 5.12M | 5.51M | 7.47M | 10.19M |
| Stockholders Equity | 7.52M | 7.52M | 5.64M | 2.42M | -105.00K | 21.34M |
Cash Flow | ||||||
| Free Cash Flow | -260.50K | -2.58M | 1.13M | -3.68M | -1.40M | -5.00M |
| Operating Cash Flow | -234.00K | -2.57M | 1.16M | -3.67M | -1.40M | -4.95M |
| Investing Cash Flow | -1.91M | -475.00K | -2.33M | -6,000 | -305.00K | -1.24M |
| Financing Cash Flow | 3.77M | 3.48M | 83.00K | 4.01M | 935.00K | -637.00K |
LBT Innovations Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CC5, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 55.28 is Neutral, neither overbought nor oversold. The STOCH value of 91.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CC5.
LBT Innovations Limited Peers Comparison
Overall Rating
AU:SEN55Neutral
AU:QFE52Neutral
AU:CYB43Neutral- AU:CC542Neutral
AU:TAL41Neutral
AU:PIL40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| AU:SEN | 55Neutral | AUD 36.47M | 84.94 | 1.06% | 15.08% | 4.73% | ― |
| AU:QFE | 52Neutral | AUD 30.04M | 0.79 | 265.43% | 108.97% | -24.21% | ― |
| AU:CYB | 43Neutral | AUD 12.41M | -1.72 | -162.05% | ― | -11.66% | 89.02% |
| AU:CC5 | 42Neutral | AUD 41.46M | -18.89 | -43.22% | ― | -15.42% | -210.00% |
| AU:TAL | 41Neutral | AUD 18.96M | -10.00 | -26.53% | ― | -42.68% | 32.10% |
| AU:PIL | 40Underperform | AUD 10.04M | -10.00 | 147.62% | ― | -29.96% | -12.50% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:CC5 | LBT Innovations Limited | 0.02 | -0.01 | -34.48% | |
| AU:SEN | Senetas Corporation Limited | 2.20 | -0.22 | -9.13% | |
| AU:QFE | QuickFee Ltd. | 0.08 | 0.04 | 105.26% | |
| AU:PIL | Peppermint Innovation Limited | 0.01 | 0.00 | 0.00% | |
| AU:CYB | Sovereign Cloud Holdings Ltd. | 0.06 | -0.02 | -26.25% | |
| AU:TAL | HSC Technology Group Ltd. | 0.06 | -0.03 | -32.10% |
LBT Innovations Limited Corporate Events
Clever Culture Systems Wins Expanded Novo Nordisk Order as APAS Nears Global Validation
Clever Culture Systems Ltd, an Adelaide-based specialist in AI microbiology automation, has secured a new purchase order from Novo Nordisk for two additional APAS® Independence instruments, lifting the pharma group’s installed base to thre...
Clever Culture Systems Files Appendix 4G, Confirms Governance Compliance
Clever Culture Systems Ltd has lodged its Appendix 4G and confirmed that its corporate governance statement for the year to 30 June 2026 is available on its website, as required under ASX listing rules. The statement, current as at 31 August 2026 and...
Clever Culture Systems Tightens Governance and Diversity Framework
Clever Culture Systems has outlined its adherence to the ASX Corporate Governance Council’s fourth‑edition principles, detailing board responsibilities, delegation to the CEO and key decisions reserved for directors, as well as processes...
Clever Culture Systems expands global footprint for FDA-cleared AI lab platform
Clever Culture Systems has positioned its APAS Independence platform as a best-in-class, AI-driven tool for automated culture plate reading in microbiology, and it is currently the only artificial intelligence technology cleared by the U.S. FDA for t...
Clever Culture Systems Swings to Loss as Revenue Falls and Costs Rise
Clever Culture Systems reported a sharp deterioration in its 2026 financial performance, with revenue falling 29.6% to $4.67 million and the group swinging from a prior-year profit to a $2.24 million net loss. The decline was driven by lower income,...
Clever Culture Systems Seeks ASX Quotation for 2.6 Million New Shares
Clever Culture Systems Limited has applied for quotation of 2,632,340 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of 13 August 2026. The securities, issued under a previously announced transaction, will in...
Clever Culture Systems Director Adjusts Equity Holdings as Options Expire
Clever Culture Systems has reported a change in the interests of director Brenton Barnes, following the expiry and lapse of 1.5 million unlisted options with an exercise price of $0.157 on 7 August 2026. Despite this disposal, Barnes maintains substa...
Clever Culture Systems Options Lapse, Trim Potential Dilution
Clever Culture Systems Limited has announced the cessation of 1,500,000 options that expired unexercised on 7 August 2026, identified as options expiring on various dates at various prices. The expiry of these options without conversion slightly redu...
Clever Culture Systems Plans November Share Placement on ASX
Clever Culture Systems Limited has notified the ASX of a proposed placement of up to 2,468,170 ordinary fully paid shares. The new securities, carrying the CC5 ticker, are planned for issue on 30 November 2026 as part of an adjustment to the company&...
Clever Culture Systems Plans New Share Placement on ASX
Clever Culture Systems Limited has notified the ASX of a proposed placement of up to 2,632,340 ordinary fully paid shares. The company has lodged the required Appendix 3B information, confirming its intention to have the new securities quoted in line...
Clever Culture Systems Doubles Pharma Customer Base and Builds APAS® Sales Pipeline
Clever Culture Systems reported a strong FY26 expansion of its APAS® Independence footprint in the pharmaceutical sector, doubling the number of large global pharma customers to eight and lifting its installed base to 34 instruments. New leases...
Clever Culture Systems Issues 16 Million Unquoted Options to Support Capital Strategy
Clever Culture Systems Limited has notified the ASX of the issue of 16 million unquoted options, each exercisable at $0.033 and expiring on June 30, 2028, with an issue date of July 1, 2026. These options, which are not intended to be quoted on the e...
Clever Culture Systems Plans New ASX-Listed Options Issue
Clever Culture Systems Limited has outlined a proposed placement involving the issue of up to 16,765,000 new options, each expiring on 30 June 2028 with an exercise price of A$0.033. The options are to form a new class of securities on the ASX, with...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 08, 2026